ArticleAging clinical and experimental research2026
Trends and prescribing patterns of antiosteoporosis medicines in Chinese patients: a real-world retrospective study.
Article in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe availability of new anti-osteoporosis medications (AOMs) and updates to clinical guidelines in recent years may have substantially influenced real-world prescribing patterns.
aimsTo assess trends in the utilization, prescribing patterns of AOMs and related influencing factors in Eastern China.
methodsPatients with osteoporosis who had at least one prescription for AOMs were identified from a provincial healthcare database in Eastern China (2019–2024). Patients were followed until the occurrence of Paget’s disease, malignant tumors, death, loss to follow-up, or October 29, 2024. The prescribing patterns and utilization trends of AOMs were analyzed. Multivariate logistic regression was performed to identify factors influencing AOMs choice.
resultsA total of 363,529 patients were included (mean age 65.1 years; 73.0% female). Active vitamin D analogs (71.9%), bisphosphonates (22.0%), traditional Chinese medicine (TCM) (15.3%) and denosumab (14.2%) were the most commonly prescribed AOMs. The use of denosumab increased significantly (2.9% vs. 21.8%, P < 0.001), while active vitamin D analogs (80.0% vs. 64.8%, P < 0.001), bisphosphonate (26.9% vs. 16.7%, P < 0.001) and TCM (15.3% vs. 11.6%, P < 0.001) declined from 2019 to 2024. Most patients received monotherapy (92.2%), with only 7.8% receiving combination therapy. The most frequent combination was vitamin D and analogs with bisphosphonates (55.6%). Women, older adults, and those with fracture history were more likely to receive calcitonin and denosumab, but less likely to receive vitamin D analogs.
conclusionsOsteoporosis treatment was predominantly monotherapy, with active vitamin D analogs being the most commonly prescribed agents, followed by bisphosphonates, TCM, and denosumab. Attention should be given to weak evidence-based TCM use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.